International, Peer Reviewed, Open Access Journal

Cancer Clinics Journal

Submit Manuscript

Cancer Clinics Journal

Cancer Clinics Journal is a peer reviewed open access journal aims to publish significant and up-to-date articles within the fields of experimental and clinical oncology including carcinogenesis - etiology, mechanisms; molecular biology; recent developments in tumor therapy; general diagnosis; laboratory diagnosis; diagnostic and experimental pathology; oncologic surgery; epidemiology and strategies for prevention, diagnosis, treatment, and cure for cancer.

Journal Features

Open Access

All the articles will be published under Open Access model.

Peer Review

Our editorial team performs strict peer-review process.

Publication Ethics

The journal follows standard guidelines to maintain transparency.

Submit Manuscript

The journal accepts all original articles, reviews and more.

About the Journal

Cancer Clinics Journal is a peer reviewed open access journal aims to publish significant and up-to-date articles within the fields of experimental and clinical oncology including carcinogenesis - etiology, mechanisms; molecular biology; recent developments in tumor therapy; general diagnosis; laboratory diagnosis; diagnostic and experimental pathology; oncologic surgery; epidemiology and strategies for prevention, diagnosis, treatment, and cure for cancer.

Open Access - Cancer Clinics Journal

Editorial Board

Soldano Ferrone - Cancer Clinics Journal

Soldano Ferrone

Harvard Medical School
United States

Girijesh Kumar Patel - Cancer Clinics Journal

Girijesh Kumar Patel

University of South Alabama
United States

Yongqing Liu - Cancer Clinics Journal

Yongqing Liu

University of Louisville
United States

Alireza Heidari - Cancer Clinics Journal

Alireza Heidari

California South University
United States

Mohammad Aslam Khan - Cancer Clinics Journal

Mohammad Aslam Khan

University of South Alabama-Mitchell Cancer Institute
United States

Maria Angelica Cortez - Cancer Clinics Journal

Maria Angelica Cortez

The University of Texas MD Anderson Cancer Center
United States

Hexin Chen - Cancer Clinics Journal

Hexin Chen

University of South Carolina
United States

Shanta M. Messerli - Cancer Clinics Journal

Shanta M. Messerli

Sanford Research
United States

Susana Maria Campos - Cancer Clinics Journal

Susana Maria Campos

Dana-Farber Cancer Institute
United States

Randa A. El-Zein - Cancer Clinics Journal

Randa A. El-Zein

Houston Methodist Hospital Houston
United States

Peter C. Hu - Cancer Clinics Journal

Peter C. Hu

The University of Texas MD Anderson Cancer Center
United States

Sanjeev K. Srivastava - Cancer Clinics Journal

Sanjeev K. Srivastava

University of South Alabama
United States

Articles

Cancer Clin J. 2019;1(1):CCJ-01-1004 | Open Access

Unusual Metastatic Thyroid Carcinoma to the Liver and the Kidneys: A Case Report

El Bez Intidhar

Papillary Thyroid Carcinoma is the most common differentiated type of thyroid malignancy. Fortunately, distant hematogenous metastases are extremely rare, including primarily lungs and bones. We report a rare case of papillary thyroid carcinoma with kidney and liver metastases, as imaged by the postoperative whole body iodine scan

CASE REPORT Updated Jul 08, 2019   PDF

Cancer Clin J. 2019;1(1):CCJ-01-1003 | Open Access

PCA3 Score Failed to Predict Prostate Cancer and Reduce the Repeat Biopsy

Cunqin Wang, Zhongjian Xu, Sheng Chen, Yuexin Ma, Yongqiang Fei, Ying Chen, Lei Wang and Hongting Wang

Purpose: To assess whether the urinary PCA3 gene test has proved helpful for diagnosing prostate cancer and reducing biopsy, we searched for pathological features that influence the shedding of PCA3 producing prostate cancer cells in urine. Methods: We detected 89 patients’ urine samples for amplification of PCA3 mRNA and PSA mRNA by transcription media amplification and ... Read More

RESEARCH ARTICLE Updated May 17, 2019   PDF

Cancer Clin J. 2018;1(1):CCJ-01-1002 | Open Access

Connexin-43 Enhances the Redesigned Cytosine Deaminase Activity for Suicide Gene Therapy in Human Breast Cancer Cells

Asif Raza and Siddhartha Sankar Ghosh

Background: The redesigned E. coli Cytosine Deaminase (CD) mutant F186W provided an excellent alternative to wild-type CD in terms of efficiency and activity. Although the redesigned F186W mutant demonstrated its superiority over the CD, there is still scope for its improvement remains to further minimize the dose-dependent cytotoxicity of the drugs. Hence, in the present study, ... Read More

RESEARCH ARTICLE Updated Jun 05, 2018   PDF

Cancer Clin J. 2018;1(1):CCJ-01-1001 | Open Access

High Dose Methotrexate in Oncological Practice: A Review and Update on Recent Trends in Administration and Management of Toxicity

Abhishek Purkayastha, Abhishek Pathak , Bhupesh Guleria , Anvesh Rathore , Sundaram Viswanath and Alpana Gupta

In cancer chemotherapy, Therapeutic Drug Monitoring (TDM) has been practical only for Methotrexate (MTX) with its main role in high doses (HDMTX) for adjuvant therapy of osteosarcoma, intracranial lymphomas, childhood leukemia and pediatric Non-Hodgkin lymphomas. HDMTX is defined as doses of 3 g/m2 to 15 g/m2 over a period of 6 hr to 24 hr. One has to ... Read More

REVIEW ARTICLE Updated May 21, 2018   PDF